Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency. Treatment of breakthrough bleeding episodes during regular prophylaxis. NovoThirteen can be used for all age groups.
Novo Nordisk announced the FDA has on 23 December 2013 approved Tretten (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine...